Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 770 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hb-SS Disease Clear all
Recruiting Not applicable Interventional

Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)

NCT05383911
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SCD Shared Decision-Making Toolkit for AYAs - including VR, SCD Shared Decision-Making Toolkit for AYAs - without VR
Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
15 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional Results available

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizuamb, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 22, 2026, 5:55 PM EDT
Completed No phase listed Observational

Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease

NCT00012545
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Trait
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 45 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

NCT05618301
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Motixafortide, Natalizumab, Leukapheresis
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients

NCT01736657
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Red blood cell exchange in sickle cell
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
12 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Oakland, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional Results available

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

NCT03593395
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Peer Mentoring [PM], Structured Education Based Transition Program STE
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Birmingham, Alabama • Mobile, Alabama • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

NCT05725902
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional

Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT

NCT04629430
View directory record Official record
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Hodgkin Lymphoma, Hodgkin Disease, Myelofibrosis, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Sickle Cell Disease, Mantle Cell Lymphoma
Interventions
Pre-biotic foods/drinks
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

NCT01590628
View directory record Official record
Conditions
Sickle Cell Disease & Thalassemia
Interventions
NiCord
Drug
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
2 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 22, 2026, 5:55 PM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 22, 2026, 5:55 PM EDT
Completed No phase listed Observational

Iron Mediated Vascular Disease in Sickle Cell Anemia Patients

NCT01239901
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Exercise on Biomarkers in SCT

NCT04273022
View directory record Official record
Conditions
Sickle Cell Trait
Interventions
Exercise
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional

Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

NCT00142051
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
nitric oxide, oxygen
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 22 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 22, 2026, 5:55 PM EDT
Recruiting Phase 2 Interventional

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

NCT07616154
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide 50mg, Abatacept, Alemtuzumab, Hydroxyurea, Thiotepa, Filgrastim, Sirolimus, Azathioprine, TBI, Hematopoietic Progenitor Cell Infusion
Drug · Radiation · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Age of Blood in Sickle Cell Transfusion

NCT03704922
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Transfusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Phase 2 Interventional

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

NCT00034528
View directory record Official record
Conditions
Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease, Thalassemia, Thalassemia Major
Interventions
Busulfan, Fludarabine, FK506, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia

NCT00004492
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
clotrimazole, hydroxyurea
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Phase 1 Interventional

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

NCT06155500
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
OTQ923
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Terminated Not applicable Interventional Results available

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

NCT01319851
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic-granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Schwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Fanconi Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia
Interventions
Alefacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 1 Interventional

Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

NCT01316796
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Chronic Hemolytic Disorders
Interventions
Sodium Nitrite Cream
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 22, 2026, 5:55 PM EDT
Withdrawn Phase 2 Interventional

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

NCT01932554
View directory record Official record
Conditions
Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions
Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen
Drug · Other
Lead sponsor
St. Louis University
Other
Eligibility
5 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 22, 2026, 5:55 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

NCT05384756
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Sirolimus
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 5:55 PM EDT
Completed Phase 2 Interventional

Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity

NCT00402480
View directory record Official record
Conditions
Stroke
Interventions
Hydroxyurea
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 22, 2026, 5:55 PM EDT
Completed No phase listed Observational Results available

Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol

NCT01783990
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
24 Months to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 22, 2026, 5:55 PM EDT